Elisabeth Oelmann
Chief Tech/Sci/R&D Officer bij NUCANA PLC
Profiel
Elisabeth Oelmann holds the position of Senior VP-Medical & Clinical Development at NuCana Plc.
In her past career she occupied the position of Senior Medical Director at Kymab Ltd., Medical Director-Oncology Europe Region at PRA International LLC and Professor at Freie Universität Berlin.
Dr. Oelmann received a doctorate from the University of Münster.
Actieve functies van Elisabeth Oelmann
Bedrijven | Functie | Begin |
---|---|---|
NUCANA PLC | Chief Tech/Sci/R&D Officer | 01-09-2020 |
Eerdere bekende functies van Elisabeth Oelmann
Bedrijven | Functie | Einde |
---|---|---|
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Corporate Officer/Principal | - |
Freie Universität Berlin | Corporate Officer/Principal | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Elisabeth Oelmann
University of Münster | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NUCANA PLC | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Health Technology |